Harbour BioMed

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

News

AbbVie begins trials of COVID-19 antibody therapy

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University.<

Astellas bets on Vir cancer drug, and other licensing deals

As year-end nears, pharma groups plump up their pipelines

AbbVie begins trials of COVID-19 antibody therapy

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks